Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse

American Journal of Gastroenterology

Volumn 102, Issue 5, 2007, Pages 1005-1012

  Montano Loza, Aldo J ^a   Carpenter, Herschel A ^a   Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PREDNISONE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; REMISSION;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; FEMALE; GAMMA-GLOBULINS; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECURRENCE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 34247860578     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01153.x     Document Type: Article

References (33)

1. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 1972 63 : 820 33.
2. Czaja AJ, Ammon HV, Summerskill WH. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980 78 : 518 23.
3. Hegarty JE, Nouri Aria KT, Portmann B, et al. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983 3 : 685 9.
4. Czaja AJ. Low dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990 11 : 1044 9.
5. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995 333 : 958 63.
6. Kanzler S, Gerken G, Lohr H, et al. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001 34 : 354 5.
7. Czaja AJ, Menon KVN, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: A retrospective analysis. Hepatology 2002 35 : 890 7.
8. Czaja AJ, Beaver SJ, Shiels MT. Sustained remission following corticosteroid therapy of severe HBsAg-negative chronic active hepatitis. Gastroenterology 1987 92 : 215 9.
9. Czaja AJ, Davis GL, Ludwig J, et al. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984 4 : 622 7.
10. Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003 23 : 116 23.
11. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999 31 : 929 38.
12. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002 36 : 479 97.
13. Czaja AJ. Treatment of autoimmune hepatitis. Semin Liver Dis 2002 22 : 365 78.
14. Carpenter HA, Czaja AJ. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 2002 6 : 685 705.
15. Summerskill WH, Korman MG, Ammon HV, et al. Prednisone for chronic active liver disease: Dose titration, standard dose, and combination with azathioprine compared. Gut 1975 16 : 876 83.
16. Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 2004 39 : 1631 8.
17. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004 40 : 644 50.
18. Soloway RD, Baggenstoss AH, Schoenfield LJ, et al. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis 1975 20 : 1087 90.
19. Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993 105 : 1824 32.
20. Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease (CALD): Correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981 80 : 687 92.
21. Theodossi A, Skene AM, Portmann B, et al. Observer variation in assessment of liver biopsies including analysis by kappa statistics. Gastroenterology 1980 79 : 232 41.
22. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001 96 : 1224 31.
23. Miyake Y, Iwasaki Y, Terada R, et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 2005 43 : 951 7.
24. Verma S, Gunuwan B, Mendler M, et al. Factors predicting relapse and poor outcome in type 1 autoimmune hepatitis: Role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004 99 : 1510 6.
25. Lohr H, Manns M, Kyriatsoulis A, et al. Clonal analysis of liver-infiltrating T-cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol 1991 84 : 297 302.
26. Page AR, Condie RM, Good RA. Suppression of plasma cell hepatitis with 6-mercaptopurine. Am J Med 1964 36 : 200 13.
27. Cohen S, Ohta G, Singer EJ, et al. Immunocytochemical study of gamma globulin in liver in hepatitis and postnecrotic cirrhosis. J Exp Med 1960 11 : 285 93.
28. Paronetto F, Rubin E, Popper H. Local formation of gamma-globulin in the diseased liver and its relation to hepatic necrosis. Lab Invest 1962 11 : 150 8.
29. Jensen DM, McFarlene IG, Portmann BS, et al. Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med 1978 299 : 1 7.
30. Cochrane AM, Moussouros A, Thomsom AD, et al. Antibody-dependent cell-mediated (K cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis. Lancet 1976 1 : 441 4.
31. Czaja AJ. Autoimmune hepatitis. Evolving concepts and treatment strategies. Dig Dis Sci 1995 40 : 435 56.
32. Czaja AJ, Bianchi FB, Carpenter HA, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005 41 : 207 15.
33. Czaja AJ, Shums Z, Norman GL. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. Autoimmunity 2004 37 : 195 201.